DownloadHi-Res Photo

Mika Naganawa, PhD

Research Scientist in Radiology and Biomedical Imaging

Research & Publications
Biography
News

Coauthors

Selected Publications

Markerless head motion tracking and event-by-event correction in brain PETZeng T, Lu Y, Jiang W, Zheng J, Zhang J, Gravel P, Wan Q, Fontaine K, Mulnix T, Jiang Y, Yang Z, Revilla E, Naganawa M, Toyonaga T, Henry S, Zhang X, Cao T, Hu L, Carson R. Markerless head motion tracking and event-by-event correction in brain PET. Physics In Medicine And Biology 2023, 68: 245019. PMID: 37983915, PMCID: PMC10713921, DOI: 10.1088/1361-6560/ad0e37.
Dose reduction in dynamic synaptic vesicle glycoprotein 2A PET imaging using artificial neural networksLi A, Yang B, Naganawa M, Fontaine K, Toyonaga T, Carson R, Tang J. Dose reduction in dynamic synaptic vesicle glycoprotein 2A PET imaging using artificial neural networks. Physics In Medicine And Biology 2023, 68: 245006. PMID: 37857316, PMCID: PMC10739622, DOI: 10.1088/1361-6560/ad0535.
The regional pattern of age-related synaptic loss in the human brain differs from gray matter volume loss: in vivo PET measurement with [11C]UCB-JToyonaga T, Khattar N, Wu Y, Lu Y, Naganawa M, Gallezot J, Matuskey D, Mecca A, Pittman B, Dias M, Nabulsi N, Finnema S, Chen M, Arnsten A, Radhakrishnan R, Skosnik P, D’Souza D, Esterlis I, Huang Y, van Dyck C, Carson R. The regional pattern of age-related synaptic loss in the human brain differs from gray matter volume loss: in vivo PET measurement with [11C]UCB-J. European Journal Of Nuclear Medicine And Molecular Imaging 2023, 51: 1012-1022. PMID: 37955791, DOI: 10.1007/s00259-023-06487-8.
Fast Reconstruction Enhances Deep Learning PET Head Motion CorrectionZeng T, Chen F, Zhang J, Lieffrig E, Cai Z, Naganawa M, You C, Lu Y, Onofrey J. Fast Reconstruction Enhances Deep Learning PET Head Motion Correction. 2023, 00: 1-1. DOI: 10.1109/nssmicrtsd49126.2023.10338189.
Fast Reconstruction for Deep Learning PET Head Motion CorrectionZeng T, Zhang J, Lieffrig E, Cai Z, Chen F, You C, Naganawa M, Lu Y, Onofrey J. Fast Reconstruction for Deep Learning PET Head Motion Correction. 2023, 14229: 710-719. PMID: 38174207, PMCID: PMC10758999, DOI: 10.1007/978-3-031-43999-5_67.
Evaluating infusion methods and simplified quantification of synaptic density in vivo with [11C]UCB-J and [18F]SynVesT-1 PETAsch R, Naganawa M, Nabulsi N, Huan Y, Esterlis I, Carson R. Evaluating infusion methods and simplified quantification of synaptic density in vivo with [11C]UCB-J and [18F]SynVesT-1 PET. Cerebrovascular And Brain Metabolism Reviews 2023, 43: 2120-2129. PMID: 37669455, PMCID: PMC10925870, DOI: 10.1177/0271678x231200423.
PET Quantification and Kinetic AnalysisCarson R, Naganawa M, Gallezot J. PET Quantification and Kinetic Analysis. 2023, 183-194. DOI: 10.1007/978-3-031-35098-6_12.
Principal component analysis of synaptic density measured with [11C]UCB-J PET in early Alzheimer’s diseaseO'Dell R, Higgins-Chen A, Gupta D, Chen M, Naganawa M, Toyonaga T, Lu Y, Ni G, Chupak A, Zhao W, Salardini E, Nabulsi N, Huang Y, Arnsten A, Carson R, van Dyck C, Mecca A. Principal component analysis of synaptic density measured with [11C]UCB-J PET in early Alzheimer’s disease. NeuroImage Clinical 2023, 39: 103457. PMID: 37422964, PMCID: PMC10338149, DOI: 10.1016/j.nicl.2023.103457.
Reductions in synaptic marker SV2A in early-course SchizophreniaYoon J, Zhang Z, Mormino E, Davidzon G, Minzenberg M, Ballon J, Kalinowski A, Hardy K, Naganawa M, Carson R, Khalighi M, Park J, Levinson D, Chin F. Reductions in synaptic marker SV2A in early-course Schizophrenia. Journal Of Psychiatric Research 2023, 161: 213-217. PMID: 36934603, DOI: 10.1016/j.jpsychires.2023.02.026.
Drug characteristics derived from kinetic modeling: combined 11C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2ANaganawa M, Gallezot J, Finnema S, Maguire R, Mercier J, Nabulsi N, Kervyn S, Henry S, Nicolas J, Huang Y, Chen M, Hannestad J, Klitgaard H, Stockis A, Carson R. Drug characteristics derived from kinetic modeling: combined 11C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2A. EJNMMI Research 2022, 12: 71. PMID: 36346513, PMCID: PMC9643320, DOI: 10.1186/s13550-022-00944-5.
Imaging of Synaptic Density in Neurodegenerative DisordersCarson RE, Naganawa M, Toyonaga T, Koohsari S, Yang Y, Chen MK, Matuskey D, Finnema SJ. Imaging of Synaptic Density in Neurodegenerative Disorders. Journal Of Nuclear Medicine 2022, 63: 60s-67s. PMID: 35649655, DOI: 10.2967/jnumed.121.263201.
Adaptive data-driven motion detection and optimized correction for brain PETRevilla EM, Gallezot JD, Naganawa M, Toyonaga T, Fontaine K, Mulnix T, Onofrey JA, Carson RE, Lu Y. Adaptive data-driven motion detection and optimized correction for brain PET. NeuroImage 2022, 252: 119031. PMID: 35257856, PMCID: PMC9206767, DOI: 10.1016/j.neuroimage.2022.119031.
Synaptic density and cognitive performance in Alzheimer's disease: A PET imaging study with [11C]UCB‐JMecca AP, O'Dell RS, Sharp ES, Banks ER, Bartlett HH, Zhao W, Lipior S, Diepenbrock NG, Chen M, Naganawa M, Toyonaga T, Nabulsi NB, Wyk B, Arnsten AFT, Huang Y, Carson RE, van Dyck C. Synaptic density and cognitive performance in Alzheimer's disease: A PET imaging study with [11C]UCB‐J. Alzheimer's & Dementia 2022, 18: 2527-2536. PMID: 35174954, PMCID: PMC9381645, DOI: 10.1002/alz.12582.
Imaging the effect of ketamine on synaptic density (SV2A) in the living brainHolmes SE, Finnema SJ, Naganawa M, DellaGioia N, Holden D, Fowles K, Davis M, Ropchan J, Emory P, Ye Y, Nabulsi N, Matuskey D, Angarita GA, Pietrzak RH, Duman RS, Sanacora G, Krystal JH, Carson RE, Esterlis I. Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. Molecular Psychiatry 2022, 27: 2273-2281. PMID: 35165397, PMCID: PMC9133063, DOI: 10.1038/s41380-022-01465-2.
Brain opioid segments and striatal patterns of dopamine release induced by naloxone and morphineShokri‐Kojori E, Naganawa M, Ramchandani VA, Wong DF, Wang G, Volkow ND. Brain opioid segments and striatal patterns of dopamine release induced by naloxone and morphine. Human Brain Mapping 2021, 43: 1419-1430. PMID: 34873784, PMCID: PMC8837588, DOI: 10.1002/hbm.25733.
Lower prefrontal cortical synaptic vesicle binding in cocaine use disorder: An exploratory 11C‐UCB‐J positron emission tomography study in humansAngarita GA, Worhunsky PD, Naganawa M, Toyonaga T, Nabulsi NB, Li C, Esterlis I, Skosnik PD, Radhakrishnan R, Pittman B, Gueorguieva R, Potenza MN, Finnema SJ, Huang Y, Carson RE, Malison RT. Lower prefrontal cortical synaptic vesicle binding in cocaine use disorder: An exploratory 11C‐UCB‐J positron emission tomography study in humans. Addiction Biology 2021, 27: e13123. PMID: 34852401, PMCID: PMC8891080, DOI: 10.1111/adb.13123.
Association of entorhinal cortical tau deposition and hippocampal synaptic density in older individuals with normal cognition and early Alzheimer's diseaseMecca AP, Chen MK, O'Dell RS, Naganawa M, Toyonaga T, Godek TA, Harris JE, Bartlett HH, Zhao W, Banks ER, Ni GS, Rogers K, Gallezot JD, Ropchan J, Emery PR, Nabulsi NB, Vander Wyk BC, Arnsten AFT, Huang Y, Carson RE, van Dyck CH. Association of entorhinal cortical tau deposition and hippocampal synaptic density in older individuals with normal cognition and early Alzheimer's disease. Neurobiology Of Aging 2021, 111: 44-53. PMID: 34963063, PMCID: PMC8761170, DOI: 10.1016/j.neurobiolaging.2021.11.004.
Generation of parametric Ki images for FDG PET using two 5‐min scansWu J, Liu H, Ye Q, Gallezot J, Naganawa M, Miao T, Lu Y, Chen M, Esserman DA, Kyriakides TC, Carson RE, Liu C. Generation of parametric Ki images for FDG PET using two 5‐min scans. Medical Physics 2021, 48: 5219-5231. PMID: 34287939, DOI: 10.1002/mp.15113.
Imaging Pituitary Vasopressin 1B Receptor in Humans with the PET Radiotracer 11C-TASP699Naganawa M, Nabulsi NB, Matuskey D, Henry S, Ropchan J, Lin SF, Gao H, Pracitto R, Labaree D, Zhang MR, Suhara T, Nishino I, Sabia H, Ozaki S, Huang Y, Carson RE. Imaging Pituitary Vasopressin 1B Receptor in Humans with the PET Radiotracer 11C-TASP699. Journal Of Nuclear Medicine 2021, 63: 609-614. PMID: 34385336, DOI: 10.2967/jnumed.121.262430.
Generation of synthetic PET images of synaptic density and amyloid from 18F‐FDG images using deep learningWang R, Liu H, Toyonaga T, Shi L, Wu J, Onofrey JA, Tsai Y, Naganawa M, Ma T, Liu Y, Chen M, Mecca AP, O’Dell R, van Dyck C, Carson RE, Liu C. Generation of synthetic PET images of synaptic density and amyloid from 18F‐FDG images using deep learning. Medical Physics 2021, 48: 5115-5129. PMID: 34224153, PMCID: PMC8455448, DOI: 10.1002/mp.15073.
In vivo evidence of lower synaptic vesicle density in schizophreniaRadhakrishnan R, Skosnik PD, Ranganathan M, Naganawa M, Toyonaga T, Finnema S, Hillmer AT, Esterlis I, Huang Y, Nabulsi N, Carson RE, D’Souza D. In vivo evidence of lower synaptic vesicle density in schizophrenia. Molecular Psychiatry 2021, 26: 7690-7698. PMID: 34135473, DOI: 10.1038/s41380-021-01184-0.
Partial volume correction analysis for 11C-UCB-J PET studies of Alzheimer's diseaseLu Y, Toyonaga T, Naganawa M, Gallezot JD, Chen MK, Mecca AP, van Dyck CH, Carson RE. Partial volume correction analysis for 11C-UCB-J PET studies of Alzheimer's disease. NeuroImage 2021, 238: 118248. PMID: 34119639, PMCID: PMC8454285, DOI: 10.1016/j.neuroimage.2021.118248.
Preliminary In Vivo Evidence of Reduced Synaptic Density in Human Immunodeficiency Virus (HIV) Despite Antiretroviral TherapyWeiss JJ, Calvi R, Naganawa M, Toyonaga T, Farhadian SF, Chintanaphol M, Chiarella J, Zheng MQ, Ropchan J, Huang Y, Pietrzak RH, Carson RE, Spudich S. Preliminary In Vivo Evidence of Reduced Synaptic Density in Human Immunodeficiency Virus (HIV) Despite Antiretroviral Therapy. Clinical Infectious Diseases 2021, 73: ciab484. PMID: 34050746, PMCID: PMC8528400, DOI: 10.1093/cid/ciab484.
Comparison of [11C]UCB-J and [18F]FDG PET in Alzheimer’s disease: A tracer kinetic modeling studyChen MK, Mecca AP, Naganawa M, Gallezot JD, Toyonaga T, Mondal J, Finnema SJ, Lin SF, O’Dell R, McDonald JW, Michalak HR, Wyk B, Nabulsi NB, Huang Y, Arnsten AF, van Dyck CH, Carson RE. Comparison of [11C]UCB-J and [18F]FDG PET in Alzheimer’s disease: A tracer kinetic modeling study. Cerebrovascular And Brain Metabolism Reviews 2021, 41: 2395-2409. PMID: 33757318, PMCID: PMC8393289, DOI: 10.1177/0271678x211004312.
PET Imaging Estimates of Regional Acetylcholine Concentration Variation in Living Human BrainSmart K, Naganawa M, Baldassarri SR, Nabulsi N, Ropchan J, Najafzadeh S, Gao H, Navarro A, Barth V, Esterlis I, Cosgrove KP, Huang Y, Carson RE, Hillmer AT. PET Imaging Estimates of Regional Acetylcholine Concentration Variation in Living Human Brain. Cerebral Cortex 2021, 31: 2787-2798. PMID: 33442731, PMCID: PMC8355478, DOI: 10.1093/cercor/bhaa387.
Assessment of test-retest reproducibility of [18F]SynVesT-1, a novel radiotracer for PET imaging of synaptic vesicle glycoprotein 2ALi S, Naganawa M, Pracitto R, Najafzadeh S, Holden D, Henry S, Matuskey D, Emery PR, Cai Z, Ropchan J, Nabulsi N, Carson RE, Huang Y. Assessment of test-retest reproducibility of [18F]SynVesT-1, a novel radiotracer for PET imaging of synaptic vesicle glycoprotein 2A. European Journal Of Nuclear Medicine And Molecular Imaging 2021, 48: 1327-1338. PMID: 33416954, DOI: 10.1007/s00259-020-05149-3.
Association of Aβ deposition and regional synaptic density in early Alzheimer’s disease: a PET imaging study with [11C]UCB-JO’Dell R, Mecca AP, Chen MK, Naganawa M, Toyonaga T, Lu Y, Godek TA, Harris JE, Bartlett HH, Banks ER, Kominek VL, Zhao W, Nabulsi NB, Ropchan J, Ye Y, Vander Wyk BC, Huang Y, Arnsten AFT, Carson RE, van Dyck CH. Association of Aβ deposition and regional synaptic density in early Alzheimer’s disease: a PET imaging study with [11C]UCB-J. Alzheimer's Research & Therapy 2021, 13: 11. PMID: 33402201, PMCID: PMC7786921, DOI: 10.1186/s13195-020-00742-y.
Assessment of population-based input functions for Patlak imaging of whole body dynamic 18F-FDG PETNaganawa M, Gallezot JD, Shah V, Mulnix T, Young C, Dias M, Chen MK, Smith AM, Carson RE. Assessment of population-based input functions for Patlak imaging of whole body dynamic 18F-FDG PET. EJNMMI Physics 2020, 7: 67. PMID: 33226522, PMCID: PMC7683759, DOI: 10.1186/s40658-020-00330-x.
PET Imaging of Synaptic Vesicle Protein 2AFinnema S, Li S, Cai Z, Naganawa M, Chen M, Matuskey D, Nabulsi N, Esterlis I, Holmes S, Radhakrishnan R, Toyonaga T, Huang Y, Carson R. PET Imaging of Synaptic Vesicle Protein 2A. 2020, 993-1019. DOI: 10.1007/978-3-030-53176-8_29.
Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorderD’Souza D, Radhakrishnan R, Naganawa M, Ganesh S, Nabulsi N, Najafzadeh S, Ropchan J, Ranganathan M, Cortes-Briones J, Huang Y, Carson RE, Skosnik P. Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorder. Molecular Psychiatry 2020, 26: 3192-3200. PMID: 32973170, DOI: 10.1038/s41380-020-00891-4.
Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [11C]UCB‐J positron emission tomography studyFinnema SJ, Toyonaga T, Detyniecki K, Chen M, Dias M, Wang Q, Lin S, Naganawa M, Gallezot J, Lu Y, Nabulsi NB, Huang Y, Spencer DD, Carson RE. Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [11C]UCB‐J positron emission tomography study. Epilepsia 2020, 61: 2183-2193. PMID: 32944949, DOI: 10.1111/epi.16653.
First-in-Human Evaluation of 18F-SynVesT-1, a Radioligand for PET Imaging of Synaptic Vesicle Glycoprotein 2ANaganawa M, Li S, Nabulsi N, Henry S, Zheng MQ, Pracitto R, Cai Z, Gao H, Kapinos M, Labaree D, Matuskey D, Huang Y, Carson RE. First-in-Human Evaluation of 18F-SynVesT-1, a Radioligand for PET Imaging of Synaptic Vesicle Glycoprotein 2A. Journal Of Nuclear Medicine 2020, 62: 561-567. PMID: 32859701, PMCID: PMC8049363, DOI: 10.2967/jnumed.120.249144.
First-in-Human Assessment of 11C-LSN3172176, an M1 Muscarinic Acetylcholine Receptor PET RadiotracerNaganawa M, Nabulsi N, Henry S, Matuskey D, Lin SF, Slieker L, Schwarz AJ, Kant N, Jesudason C, Ruley K, Navarro A, Gao H, Ropchan J, Labaree D, Carson RE, Huang Y. First-in-Human Assessment of 11C-LSN3172176, an M1 Muscarinic Acetylcholine Receptor PET Radiotracer. Journal Of Nuclear Medicine 2020, 62: 553-560. PMID: 32859711, PMCID: PMC8049371, DOI: 10.2967/jnumed.120.246967.
Simplified Quantification of 11C-UCB-J PET Evaluated in a Large Human CohortNaganawa M, Gallezot JD, Finnema SJ, Matuskey D, Mecca A, Nabulsi NB, Labaree D, Ropchan J, Malison RT, D'Souza DC, Esterlis I, Detyniecki K, van Dyck CH, Huang Y, Carson RE. Simplified Quantification of 11C-UCB-J PET Evaluated in a Large Human Cohort. Journal Of Nuclear Medicine 2020, 62: 418-421. PMID: 32646875, PMCID: PMC8049341, DOI: 10.2967/jnumed.120.243949.
In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PETMecca AP, Chen M, O'Dell RS, Naganawa M, Toyonaga T, Godek TA, Harris JE, Bartlett HH, Zhao W, Nabulsi NB, Wyk BCV, Varma P, Arnsten AFT, Huang Y, Carson RE, van Dyck C. In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET. Alzheimer's & Dementia 2020, 16: 974-982. PMID: 32400950, PMCID: PMC7383876, DOI: 10.1002/alz.12097.
Kinetic Modeling and Test–Retest Reproducibility of 11C-EKAP and 11C-FEKAP, Novel Agonist Radiotracers for PET Imaging of the κ-Opioid Receptor in HumansNaganawa M, Li S, Nabulsi N, Lin SF, Labaree D, Ropchan J, Gao H, Mei M, Henry S, Matuskey D, Carson RE, Huang Y. Kinetic Modeling and Test–Retest Reproducibility of 11C-EKAP and 11C-FEKAP, Novel Agonist Radiotracers for PET Imaging of the κ-Opioid Receptor in Humans. Journal Of Nuclear Medicine 2020, 61: 1636-1642. PMID: 32169917, PMCID: PMC9364890, DOI: 10.2967/jnumed.119.227694.
Synaptic Changes in Parkinson Disease Assessed with in vivo ImagingMatuskey D, Tinaz S, Wilcox KC, Naganawa M, Toyonaga T, Dias M, Henry S, Pittman B, Ropchan J, Nabulsi N, Suridjan I, Comley RA, Huang Y, Finnema SJ, Carson RE. Synaptic Changes in Parkinson Disease Assessed with in vivo Imaging. Annals Of Neurology 2020, 87: 329-338. PMID: 31953875, PMCID: PMC7065227, DOI: 10.1002/ana.25682.
Data-Driven Motion Detection and Event-by-Event Correction for Brain PET: Comparison with VicraLu Y, Naganawa M, Toyonaga T, Gallezot JD, Fontaine K, Ren S, Revilla EM, Mulnix T, Carson RE. Data-Driven Motion Detection and Event-by-Event Correction for Brain PET: Comparison with Vicra. Journal Of Nuclear Medicine 2020, 61: 1397-1403. PMID: 32005770, PMCID: PMC7456171, DOI: 10.2967/jnumed.119.235515.
PET Imaging of Pancreatic Dopamine D2 and D3 Receptor Density with 11C-(+)-PHNO in Type 1 DiabetesBini J, Sanchez-Rangel E, Gallezot JD, Naganawa M, Nabulsi N, Lim K, Najafzadeh S, Shirali A, Ropchan J, Matuskey D, Huang Y, Herold K, Harris PE, Sherwin RS, Carson RE, Cline GW. PET Imaging of Pancreatic Dopamine D2 and D3 Receptor Density with 11C-(+)-PHNO in Type 1 Diabetes. Journal Of Nuclear Medicine 2019, 61: 570-576. PMID: 31601695, PMCID: PMC7198375, DOI: 10.2967/jnumed.119.234013.
Assessment of a white matter reference region for 11C-UCB-J PET quantificationRossano S, Toyonaga T, Finnema SJ, Naganawa M, Lu Y, Nabulsi N, Ropchan J, De Bruyn S, Otoul C, Stockis A, Nicolas JM, Martin P, Mercier J, Huang Y, Maguire RP, Carson RE. Assessment of a white matter reference region for 11C-UCB-J PET quantification. Cerebrovascular And Brain Metabolism Reviews 2019, 40: 1890-1901. PMID: 31570041, PMCID: PMC7446568, DOI: 10.1177/0271678x19879230.
Atlas-Based Multiorgan Segmentation for Dynamic Abdominal PETRen S, Laub P, Lu Y, Naganawa M, Carson R. Atlas-Based Multiorgan Segmentation for Dynamic Abdominal PET. IEEE Transactions On Radiation And Plasma Medical Sciences 2019, 4: 50-62. DOI: 10.1109/trpms.2019.2926889.
In Vivo Synaptic Density Imaging with 11C-UCB-J Detects Treatment Effects of Saracatinib in a Mouse Model of Alzheimer DiseaseToyonaga T, Smith LM, Finnema SJ, Gallezot JD, Naganawa M, Bini J, Mulnix T, Cai Z, Ropchan J, Huang Y, Strittmatter SM, Carson RE. In Vivo Synaptic Density Imaging with 11C-UCB-J Detects Treatment Effects of Saracatinib in a Mouse Model of Alzheimer Disease. Journal Of Nuclear Medicine 2019, 60: 1780-1786. PMID: 31101744, PMCID: PMC6894376, DOI: 10.2967/jnumed.118.223867.
Lower synaptic density is associated with depression severity and network alterationsHolmes SE, Scheinost D, Finnema SJ, Naganawa M, Davis MT, DellaGioia N, Nabulsi N, Matuskey D, Angarita GA, Pietrzak RH, Duman RS, Sanacora G, Krystal JH, Carson RE, Esterlis I. Lower synaptic density is associated with depression severity and network alterations. Nature Communications 2019, 10: 1529. PMID: 30948709, PMCID: PMC6449365, DOI: 10.1038/s41467-019-09562-7.
Parametric Imaging With PET and SPECTGallezot J, Lu Y, Naganawa M, Carson R. Parametric Imaging With PET and SPECT. IEEE Transactions On Radiation And Plasma Medical Sciences 2019, 4: 1-23. DOI: 10.1109/trpms.2019.2908633.
Social status and demographic effects of the kappa opioid receptor: a PET imaging study with a novel agonist radiotracer in healthy volunteersMatuskey D, Dias M, Naganawa M, Pittman B, Henry S, Li S, Gao H, Ropchan J, Nabulsi N, Carson RE, Huang Y. Social status and demographic effects of the kappa opioid receptor: a PET imaging study with a novel agonist radiotracer in healthy volunteers. Neuropsychopharmacology 2019, 44: 1714-1719. PMID: 30928993, PMCID: PMC6785144, DOI: 10.1038/s41386-019-0379-7.
A single‐center, open‐label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteersFinnema SJ, Rossano S, Naganawa M, Henry S, Gao H, Pracitto R, Maguire RP, Mercier J, Kervyn S, Nicolas J, Klitgaard H, DeBruyn S, Otoul C, Martin P, Muglia P, Matuskey D, Nabulsi NB, Huang Y, Kaminski RM, Hannestad J, Stockis A, Carson RE. A single‐center, open‐label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers. Epilepsia 2019, 60: 958-967. PMID: 30924924, PMCID: PMC6532410, DOI: 10.1111/epi.14701.
Data-driven voluntary body motion detection and non-rigid event-by-event correction for static and dynamic PETLu Y, Gallezot JD, Naganawa M, Ren S, Fontaine K, Wu J, Onofrey JA, Toyonaga T, Boutagy N, Mulnix T, Panin VY, Casey ME, Carson RE, Liu C. Data-driven voluntary body motion detection and non-rigid event-by-event correction for static and dynamic PET. Physics In Medicine And Biology 2019, 64: 065002. PMID: 30695768, DOI: 10.1088/1361-6560/ab02c2.
Novel Kappa Opioid Receptor Agonist as Improved PET Radiotracer: Development and in Vivo EvaluationLi S, Zheng M, Naganawa M, Gao H, Pracitto R, Shirali A, Lin SF, Teng JK, Ropchan J, Huang Y. Novel Kappa Opioid Receptor Agonist as Improved PET Radiotracer: Development and in Vivo Evaluation. Molecular Pharmaceutics 2019, 16: 1523-1531. PMID: 30726092, DOI: 10.1021/acs.molpharmaceut.8b01209.
Development and In Vivo Evaluation of a κ-Opioid Receptor Agonist as a PET Radiotracer with Superior Imaging CharacteristicsLi S, Zheng MQ, Naganawa M, Kim S, Gao H, Kapinos M, Labaree D, Huang Y. Development and In Vivo Evaluation of a κ-Opioid Receptor Agonist as a PET Radiotracer with Superior Imaging Characteristics. Journal Of Nuclear Medicine 2019, 60: 1023-1030. PMID: 30630942, PMCID: PMC6604690, DOI: 10.2967/jnumed.118.220517.
Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic ImagingChen MK, Mecca AP, Naganawa M, Finnema SJ, Toyonaga T, Lin SF, Najafzadeh S, Ropchan J, Lu Y, McDonald JW, Michalak HR, Nabulsi NB, Arnsten AFT, Huang Y, Carson RE, van Dyck CH. Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging. JAMA Neurology 2018, 75: 1215-1224. PMID: 30014145, PMCID: PMC6233853, DOI: 10.1001/jamaneurol.2018.1836.
Improved discrimination between benign and malignant LDCT screening-detected lung nodules with dynamic over static 18F-FDG PET as a function of injected doseYe Q, Wu J, Lu Y, Naganawa M, Gallezot JD, Ma T, Liu Y, Tanoue L, Detterbeck F, Blasberg J, Chen MK, Casey M, Carson RE, Liu C. Improved discrimination between benign and malignant LDCT screening-detected lung nodules with dynamic over static 18F-FDG PET as a function of injected dose. Physics In Medicine And Biology 2018, 63: 175015. PMID: 30095083, PMCID: PMC6158045, DOI: 10.1088/1361-6560/aad97f.
Decreased VMAT2 in the pancreas of humans with type 2 diabetes mellitus measured in vivo by PET imagingCline GW, Naganawa M, Chen L, Chidsey K, Carvajal-Gonzalez S, Pawlak S, Rossulek M, Zhang Y, Bini J, McCarthy TJ, Carson RE, Calle RA. Decreased VMAT2 in the pancreas of humans with type 2 diabetes mellitus measured in vivo by PET imaging. Diabetologia 2018, 61: 2598-2607. PMID: 29721633, DOI: 10.1007/s00125-018-4624-0.
Evaluation of Pancreatic VMAT2 Binding with Active and Inactive Enantiomers of [18F]FP-DTBZ in Healthy Subjects and Patients with Type 1 DiabetesNaganawa M, Lim K, Nabulsi NB, Lin SF, Labaree D, Ropchan J, Herold KC, Huang Y, Harris P, Ichise M, Cline GW, Carson RE. Evaluation of Pancreatic VMAT2 Binding with Active and Inactive Enantiomers of [18F]FP-DTBZ in Healthy Subjects and Patients with Type 1 Diabetes. Molecular Imaging And Biology 2018, 20: 835-845. PMID: 29468404, PMCID: PMC6533199, DOI: 10.1007/s11307-018-1170-6.
Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia SubjectsD’Souza D, Carson RE, Driesen N, Johannesen J, Ranganathan M, Krystal JH, Ahn K, Bielen K, Carbuto M, Deaso E, D’Souza D, Ranganathan M, Naganawa M, Ranganathan M, D’Souza D, Nabulsi N, Zheng M, Lin S, Huang Y, Carson R, Driesen N, Ahn K, Morgan P, Suckow R, He G, McCarthy G, Krystal J, Johannesen J, Kenney J, Gelernter J, Gueorguieva R, Pittman B. Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects. Biological Psychiatry 2018, 84: 413-421. PMID: 29499855, PMCID: PMC6068006, DOI: 10.1016/j.biopsych.2017.12.019.
Evaluation of PET Brain Radioligands for Imaging Pancreatic β-Cell Mass: Potential Utility of 11C-(+)-PHNOBini J, Naganawa M, Nabulsi N, Huang Y, Ropchan J, Lim K, Najafzadeh S, Herold KC, Cline GW, Carson RE. Evaluation of PET Brain Radioligands for Imaging Pancreatic β-Cell Mass: Potential Utility of 11C-(+)-PHNO. Journal Of Nuclear Medicine 2018, 59: 1249-1254. PMID: 29371405, PMCID: PMC6071501, DOI: 10.2967/jnumed.117.197285.
Quantitative PET Imaging in Drug Development: Estimation of Target OccupancyNaganawa M, Gallezot JD, Rossano S, Carson RE. Quantitative PET Imaging in Drug Development: Estimation of Target Occupancy. Bulletin Of Mathematical Biology 2017, 81: 3508-3541. PMID: 29230702, DOI: 10.1007/s11538-017-0374-2.
Novel 18F-Labeled κ-Opioid Receptor Antagonist as PET Radiotracer: Synthesis and In Vivo Evaluation of 18F-LY2459989 in Nonhuman PrimatesLi S, Cai Z, Zheng MQ, Holden D, Naganawa M, Lin SF, Ropchan J, Labaree D, Kapinos M, Lara-Jaime T, Navarro A, Huang Y. Novel 18F-Labeled κ-Opioid Receptor Antagonist as PET Radiotracer: Synthesis and In Vivo Evaluation of 18F-LY2459989 in Nonhuman Primates. Journal Of Nuclear Medicine 2017, 59: 140-146. PMID: 28747521, PMCID: PMC5750518, DOI: 10.2967/jnumed.117.195586.
Evaluation of pancreatic VMAT2 binding with active and inactive enantiomers of 18F-FP-DTBZ in baboonsNaganawa M, Lin SF, Lim K, Labaree D, Ropchan J, Harris P, Huang Y, Ichise M, Carson RE, Cline GW. Evaluation of pancreatic VMAT2 binding with active and inactive enantiomers of 18F-FP-DTBZ in baboons. Nuclear Medicine And Biology 2016, 43: 743-751. PMID: 27673755, PMCID: PMC5248981, DOI: 10.1016/j.nucmedbio.2016.08.018.
Preclinical Evaluation of 18F-PF-05270430, a Novel PET Radioligand for the Phosphodiesterase 2A EnzymeChen L, Nabulsi N, Naganawa M, Zasadny K, Skaddan MB, Zhang L, Najafzadeh S, Lin SF, Helal CJ, Boyden TL, Chang C, Ropchan J, Carson RE, Villalobos A, Huang Y. Preclinical Evaluation of 18F-PF-05270430, a Novel PET Radioligand for the Phosphodiesterase 2A Enzyme. Journal Of Nuclear Medicine 2016, 57: 1448-1453. PMID: 27199356, PMCID: PMC5093921, DOI: 10.2967/jnumed.115.171454.
First-in-Human Assessment of the Novel PDE2A PET Radiotracer 18F-PF-05270430Naganawa M, Waterhouse RN, Nabulsi N, Lin SF, Labaree D, Ropchan J, Tarabar S, DeMartinis N, Ogden A, Banerjee A, Huang Y, Carson RE. First-in-Human Assessment of the Novel PDE2A PET Radiotracer 18F-PF-05270430. Journal Of Nuclear Medicine 2016, 57: 1388-1395. PMID: 27103022, PMCID: PMC5093918, DOI: 10.2967/jnumed.115.166850.
Event-by-Event Continuous Respiratory Motion Correction for Dynamic PET ImagingYu Y, Chan C, Ma T, Liu Y, Gallezot JD, Naganawa M, Kelada OJ, Germino M, Sinusas AJ, Carson RE, Liu C. Event-by-Event Continuous Respiratory Motion Correction for Dynamic PET Imaging. Journal Of Nuclear Medicine 2016, 57: 1084-1090. PMID: 26912437, DOI: 10.2967/jnumed.115.167676.
Comparative evaluation of two glycine transporter 1 radiotracers [11C]GSK931145 and [18F]MK‐6577 in baboonsZheng MQ, Lin SF, Holden D, Naganawa M, Ropchan JR, Najafzaden S, Kapinos M, Tabriz M, Carson RE, Hamill TG, Huang Y. Comparative evaluation of two glycine transporter 1 radiotracers [11C]GSK931145 and [18F]MK‐6577 in baboons. Synapse 2016, 70: 112-120. PMID: 26671330, DOI: 10.1002/syn.21879.
Receptor Occupancy of the κ-Opioid Antagonist LY2456302 Measured with Positron Emission Tomography and the Novel Radiotracer 11C-LY2795050Naganawa M, Dickinson GL, Zheng MQ, Henry S, Vandenhende F, Witcher J, Bell R, Nabulsi N, Lin SF, Ropchan J, Neumeister A, Ranganathan M, Tauscher J, Huang Y, Carson RE. Receptor Occupancy of the κ-Opioid Antagonist LY2456302 Measured with Positron Emission Tomography and the Novel Radiotracer 11C-LY2795050. Journal Of Pharmacology And Experimental Therapeutics 2015, 356: 260-266. PMID: 26628406, PMCID: PMC4727157, DOI: 10.1124/jpet.115.229278.
Test–Retest Reproducibility of Binding Parameters in Humans with 11C-LY2795050, an Antagonist PET Radiotracer for the κ Opioid ReceptorNaganawa M, Zheng MQ, Henry S, Nabulsi N, Lin SF, Ropchan J, Labaree D, Najafzadeh S, Kapinos M, Tauscher J, Neumeister A, Carson RE, Huang Y. Test–Retest Reproducibility of Binding Parameters in Humans with 11C-LY2795050, an Antagonist PET Radiotracer for the κ Opioid Receptor. Journal Of Nuclear Medicine 2015, 56: 243-248. PMID: 25593119, PMCID: PMC4322754, DOI: 10.2967/jnumed.114.147975.
Test-retest variability of adenosine A2A binding in the human brain with 11C-TMSX and PETNaganawa M, Mishina M, Sakata M, Oda K, Hiura M, Ishii K, Ishiwata K. Test-retest variability of adenosine A2A binding in the human brain with 11C-TMSX and PET. EJNMMI Research 2014, 4: 76. PMID: 25621197, PMCID: PMC4293456, DOI: 10.1186/s13550-014-0076-9.
Kinetic Modeling of 11C-LY2795050, A Novel Antagonist Radiotracer for PET Imaging of the Kappa Opioid Receptor in HumansNaganawa M, Zheng MQ, Nabulsi N, Tomasi G, Henry S, Lin SF, Ropchan J, Labaree D, Tauscher J, Neumeister A, Carson RE, Huang Y. Kinetic Modeling of 11C-LY2795050, A Novel Antagonist Radiotracer for PET Imaging of the Kappa Opioid Receptor in Humans. Cerebrovascular And Brain Metabolism Reviews 2014, 34: 1818-1825. PMID: 25182664, PMCID: PMC4269759, DOI: 10.1038/jcbfm.2014.150.
Evaluation of the agonist PET radioligand [11C]GR103545 to image kappa opioid receptor in humans: Kinetic model selection, test–retest reproducibility and receptor occupancy by the antagonist PF-04455242Naganawa M, Jacobsen LK, Zheng MQ, Lin SF, Banerjee A, Byon W, Weinzimmer D, Tomasi G, Nabulsi N, Grimwood S, Badura LL, Carson RE, McCarthy TJ, Huang Y. Evaluation of the agonist PET radioligand [11C]GR103545 to image kappa opioid receptor in humans: Kinetic model selection, test–retest reproducibility and receptor occupancy by the antagonist PF-04455242. NeuroImage 2014, 99: 69-79. PMID: 24844744, PMCID: PMC4140089, DOI: 10.1016/j.neuroimage.2014.05.033.
Event‐by‐event respiratory motion correction for PET with 3D internal‐1D external motion correlationChan C, Jin X, Fung EK, Naganawa M, Mulnix T, Carson RE, Liu C. Event‐by‐event respiratory motion correction for PET with 3D internal‐1D external motion correlation. Medical Physics 2013, 40: 112507. PMID: 24320466, DOI: 10.1118/1.4826165.
Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHDDing YS, Naganawa M, Gallezot JD, Nabulsi N, Lin SF, Ropchan J, Weinzimmer D, McCarthy TJ, Carson RE, Huang Y, Laruelle M. Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHD. NeuroImage 2013, 86: 164-171. PMID: 23933039, DOI: 10.1016/j.neuroimage.2013.08.001.
Tracer Kinetic Modeling of [11C]AFM, a New PET Imaging Agent for the Serotonin TransporterNaganawa M, Nabulsi N, Planeta B, Gallezot JD, Lin SF, Najafzadeh S, Williams W, Ropchan J, Labaree D, Neumeister A, Huang Y, Carson RE. Tracer Kinetic Modeling of [11C]AFM, a New PET Imaging Agent for the Serotonin Transporter. Cerebrovascular And Brain Metabolism Reviews 2013, 33: 1886-1896. PMID: 23921898, PMCID: PMC3851894, DOI: 10.1038/jcbfm.2013.134.
Differential effects of age on human striatal adenosine A1 and A2A receptorsMishina M, Kimura Y, Naganawa M, Ishii K, Oda K, Sakata M, Toyohara J, Kobayashi S, Katayama Y, Ishiwata K. Differential effects of age on human striatal adenosine A1 and A2A receptors. Synapse 2012, 66: 832-839. PMID: 22623181, DOI: 10.1002/syn.21573.
Quantification of Neuroreceptors and NeurotransportersIto H, Naganawa M, Seki C, Takano H, Kanno I, Suhara T. Quantification of Neuroreceptors and Neurotransporters. 2012, 71: 149-161. DOI: 10.1007/7657_2012_44.
Adenosine A2A Receptors Measured with [11C]TMSX PET in the Striata of Parkinson's Disease PatientsMishina M, Ishiwata K, Naganawa M, Kimura Y, Kitamura S, Suzuki M, Hashimoto M, Ishibashi K, Oda K, Sakata M, Hamamoto M, Kobayashi S, Katayama Y, Ishii K. Adenosine A2A Receptors Measured with [11C]TMSX PET in the Striata of Parkinson's Disease Patients. PLOS ONE 2011, 6: e17338. PMID: 21386999, PMCID: PMC3046146, DOI: 10.1371/journal.pone.0017338.
Imaging of I2-imidazoline receptors by small-animal PET using 2-(3-fluoro-[4-11C]tolyl)-4,5-dihydro-1H-imidazole ([11C]FTIMD)Kawamura K, Naganawa M, Konno F, Yui J, Wakizaka H, Yamasaki T, Yanamoto K, Hatori A, Takei M, Yoshida Y, Sakaguchi K, Fukumura T, Kimura Y, Zhang MR. Imaging of I2-imidazoline receptors by small-animal PET using 2-(3-fluoro-[4-11C]tolyl)-4,5-dihydro-1H-imidazole ([11C]FTIMD). Nuclear Medicine And Biology 2010, 37: 625-635. PMID: 20610167, DOI: 10.1016/j.nucmedbio.2010.02.013.
A new graphic plot analysis for determination of neuroreceptor binding in positron emission tomography studiesIto H, Yokoi T, Ikoma Y, Shidahara M, Seki C, Naganawa M, Takahashi H, Takano H, Kimura Y, Ichise M, Suhara T. A new graphic plot analysis for determination of neuroreceptor binding in positron emission tomography studies. NeuroImage 2009, 49: 578-586. PMID: 19631754, DOI: 10.1016/j.neuroimage.2009.07.021.
Improvement of likelihood estimation in Logan graphical analysis using maximum a posteriori for neuroreceptor PET imagingShidahara M, Seki C, Naganawa M, Sakata M, Ishikawa M, Ito H, Kanno I, Ishiwata K, Kimura Y. Improvement of likelihood estimation in Logan graphical analysis using maximum a posteriori for neuroreceptor PET imaging. Annals Of Nuclear Medicine 2009, 23: 163-171. PMID: 19225940, DOI: 10.1007/s12149-008-0226-0.
Shortened protocol in practical [11C]SA4503-PET studies for sigma1 receptor quantificationSakata M, Kimura Y, Naganawa M, Ishikawa M, Oda K, Ishii K, Hashimoto K, Chihara K, Ishiwata K. Shortened protocol in practical [11C]SA4503-PET studies for sigma1 receptor quantification. Annals Of Nuclear Medicine 2008, 22: 143-146. PMID: 18311540, DOI: 10.1007/s12149-007-0088-x.
PET kinetic analysis: error consideration of quantitative analysis in dynamic studiesIkoma Y, Watabe H, Shidahara M, Naganawa M, Kimura Y. PET kinetic analysis: error consideration of quantitative analysis in dynamic studies. Annals Of Nuclear Medicine 2008, 22: 1-11. PMID: 18250982, DOI: 10.1007/s12149-007-0083-2.
Robust estimation of the arterial input function for Logan plots using an intersectional searching algorithm and clustering in positron emission tomography for neuroreceptor imagingNaganawa M, Kimura Y, Yano J, Mishina M, Yanagisawa M, Ishii K, Oda K, Ishiwata K. Robust estimation of the arterial input function for Logan plots using an intersectional searching algorithm and clustering in positron emission tomography for neuroreceptor imaging. NeuroImage 2007, 40: 26-34. PMID: 18187345, DOI: 10.1016/j.neuroimage.2007.11.035.
Distribution volume as an alternative to the binding potential for sigma1 receptor imagingKimura Y, Naganawa M, Sakata M, Ishikawa M, Mishina M, Oda K, Ishii K, Ishiwata K. Distribution volume as an alternative to the binding potential for sigma1 receptor imaging. Annals Of Nuclear Medicine 2007, 21: 533-535. PMID: 18030587, DOI: 10.1007/s12149-007-0063-6.
Wavelet denoising for voxel-based compartmental analysis of peripheral benzodiazepine receptors with 18F-FEDAA1106Shidahara M, Ikoma Y, Seki C, Fujimura Y, Naganawa M, Ito H, Suhara T, Kanno I, Kimura Y. Wavelet denoising for voxel-based compartmental analysis of peripheral benzodiazepine receptors with 18F-FEDAA1106. European Journal Of Nuclear Medicine And Molecular Imaging 2007, 35: 416. PMID: 18026949, DOI: 10.1007/s00259-007-0623-y.
PET kinetic analysis: wavelet denoising of dynamic PET data with application to parametric imagingShidahara M, Ikoma Y, Kershaw J, Kimura Y, Naganawa M, Watabe H. PET kinetic analysis: wavelet denoising of dynamic PET data with application to parametric imaging. Annals Of Nuclear Medicine 2007, 21: 379. PMID: 17876550, DOI: 10.1007/s12149-007-0044-9.
Temporal and spatial blood information estimation using Bayesian ICA in dynamic cerebral positron emission tomographyNaganawa M, Kimura Y, Ishii K, Oda K, Ishiwata K. Temporal and spatial blood information estimation using Bayesian ICA in dynamic cerebral positron emission tomography. Digital Signal Processing 2007, 17: 979-993. DOI: 10.1016/j.dsp.2007.03.002.
High Occupancy of Sigma-1 Receptors in the Human Brain after Single Oral Administration of Fluvoxamine: A Positron Emission Tomography Study Using [11C]SA4503Ishikawa M, Ishiwata K, Ishii K, Kimura Y, Sakata M, Naganawa M, Oda K, Miyatake R, Fujisaki M, Shimizu E, Shirayama Y, Iyo M, Hashimoto K. High Occupancy of Sigma-1 Receptors in the Human Brain after Single Oral Administration of Fluvoxamine: A Positron Emission Tomography Study Using [11C]SA4503. Biological Psychiatry 2007, 62: 878-883. PMID: 17662961, DOI: 10.1016/j.biopsych.2007.04.001.
Evaluation of distribution of adenosine A2A receptors in normal human brain measured with [11C]TMSX PETMishina M, Ishiwata K, Kimura Y, Naganawa M, Oda K, Kobayashi S, Katayama Y, Ishii K. Evaluation of distribution of adenosine A2A receptors in normal human brain measured with [11C]TMSX PET. Synapse 2007, 61: 778-784. PMID: 17568431, DOI: 10.1002/syn.20423.
Mapping of human cerebral sigma1 receptors using positron emission tomography and [11C]SA4503Sakata M, Kimura Y, Naganawa M, Oda K, Ishii K, Chihara K, Ishiwata K. Mapping of human cerebral sigma1 receptors using positron emission tomography and [11C]SA4503. NeuroImage 2007, 35: 1-8. PMID: 17240168, DOI: 10.1016/j.neuroimage.2006.11.055.
PET kinetic analysis —Pitfalls and a solution for the Logan plotKimura Y, Naganawa M, Shidahara M, Ikoma Y, Watabe H. PET kinetic analysis —Pitfalls and a solution for the Logan plot. Annals Of Nuclear Medicine 2007, 21: 1-8. PMID: 17373330, DOI: 10.1007/bf03033993.
Quantification of adenosine A2A receptors in the human brain using [11C]TMSX and positron emission tomographyNaganawa M, Kimura Y, Mishina M, Manabe Y, Chihara K, Oda K, Ishii K, Ishiwata K. Quantification of adenosine A2A receptors in the human brain using [11C]TMSX and positron emission tomography. European Journal Of Nuclear Medicine And Molecular Imaging 2006, 34: 679-687. PMID: 17171358, DOI: 10.1007/s00259-006-0294-0.
PET kinetic analysis—compartmental modelWatabe H, Ikoma Y, Kimura Y, Naganawa M, Shidahara M. PET kinetic analysis—compartmental model. Annals Of Nuclear Medicine 2006, 20: 583. PMID: 17294668, DOI: 10.1007/bf02984655.
A feasibility study of [11C]SA4503-PET for evaluating sigma1 receptor occupancy by neuroleptics: The binding of haloperidol to sigma1 and dopamine D2-like receptorsIshiwata K, Oda K, Sakata M, Kimura Y, Kawamura K, Oda K, Sasaki T, Naganawa M, Chihara K, Okubo Y, Ishii K. A feasibility study of [11C]SA4503-PET for evaluating sigma1 receptor occupancy by neuroleptics: The binding of haloperidol to sigma1 and dopamine D2-like receptors. Annals Of Nuclear Medicine 2006, 20: 569-573. PMID: 17134027, DOI: 10.1007/bf03026824.
MAP-based kinetic analysis for voxel-by-voxel compartment model estimation: Detailed imaging of the cerebral glucose metabolism using FDGKimura Y, Naganawa M, Yamaguchi J, Takabayashi Y, Uchiyama A, Oda K, Ishii K, Ishiwata K. MAP-based kinetic analysis for voxel-by-voxel compartment model estimation: Detailed imaging of the cerebral glucose metabolism using FDG. NeuroImage 2005, 29: 1203-1211. PMID: 16216532, DOI: 10.1016/j.neuroimage.2005.08.046.
Omission of serial arterial blood sampling in neuroreceptor imaging with independent component analysisNaganawa M, Kimura Y, Nariai T, Ishii K, Oda K, Manabe Y, Chihara K, Ishiwata K. Omission of serial arterial blood sampling in neuroreceptor imaging with independent component analysis. NeuroImage 2005, 26: 885-890. PMID: 15955498, DOI: 10.1016/j.neuroimage.2005.02.025.
Extraction of a plasma time-activity curve from dynamic brain PET images based on independent component analysisNaganawa M, Kimura Y, Ishii K, Oda K, Ishiwata K, Matani A. Extraction of a plasma time-activity curve from dynamic brain PET images based on independent component analysis. IEEE Transactions On Biomedical Engineering 2005, 52: 201-210. PMID: 15709657, DOI: 10.1109/tbme.2004.840193.

Edit Profile

Contact Information

Research & Publications

Biography

News

Coauthors

Selected Publications